CoChat

Naloxone Suppresses Buprenorphine Stimulation of Plasma Prolactin

MENDELSON, JACK H., MELLO, NANCY K., TEOH, SIEW K., LLOYD-JONES, JOHN G., CLIFFORD, JOHN M. · 1989 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record.

Abstract

The effects of parenterally-administered buprenorphine and simultaneous injection of naloxone was evaluated in six healthy adult males. Each subject was studied on six occasions, an average of 10 days apart, and received either two simultaneous intramuscular injections of saline, buprenorphine 0.3 mg and saline, or buprenorphine 0.3 mg and 0.6 mg, 0.45 mg, 0.3 mg, or 0.15 mg of naloxone. Simultaneous injection of buprenorphine 0.3 mg and saline resulted in an average increase in plasma prolactin above baseline levels of approximately 10 and 25 ng/ml, 30 and 55 minutes after injection. Buprenorphine-induced stimulation of plasma prolactin levels was statistically significantly greater than basal prolactin values (p less than 0.01). When 0.6 mg of naloxone was simultaneously injected with 0.3 mg buprenorphine, peak plasma prolactin levels were significantly lower (p less than 0.05) than prolactin values after administration of 0.3 mg buprenorphine and saline. Simultaneous injection of 0.45 mg naloxone and 0.3 mg buprenorphine also resulted in a significant attenuation (p less than 0.05) of buprenorphine-stimulated prolactin levels. Injection of 0.3 mg or 0.15 mg of naloxone did not inhibit prolactin stimulation produced by buprenorphine 0.3 mg. These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004714-198904000-00006

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 11

Metadata

Authors
MENDELSON, J. H., MELLO, N. K., TEOH, S. K., LLOYD-JONES, J. G., & CLIFFORD, J. M.
Affiliations
  • Harvard University (US)
  • Reckitt Benckiser Health Limited (United Kingdom) (GB)
Venue
Journal of Clinical Psychopharmacology
Published
1989-04
Volume
9
Issue
2
Pages
105-109
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2021916539
Cited by
11
References
0
Citations by year
2024: 1 · 2021: 1 · 2019: 1 · 2017: 1
FWCI
0.00
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Drug Abuse (DA-04059, DA 00064, DA00101)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
buprenorphine, naloxone, prolactin, opioid agonists, opioid antagonists, dose-response relationship, abuse liability, opiate abuse, parenteral administration
MeSH terms
Adolescent, Adult, Buprenorphine, Humans, Injections, Intramuscular, Male, Naloxone, Prolactin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Naloxone Suppresses Buprenorphine Stimulation of Plasma Prolactin. https://app.cochat.ai/papers/10.1097/00004714-198904000-00006
The paper
MENDELSON, J. H., MELLO, N. K., TEOH, S. K., LLOYD-JONES, J. G., & CLIFFORD, J. M. (1989). Naloxone Suppresses Buprenorphine Stimulation of Plasma Prolactin. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198904000-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.